Journey Medical Q3 EPS Forecast Increased by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Analysts at Roth Capital lifted their Q3 2025 earnings per share estimates for Journey Medical in a research report issued to clients and investors on Thursday, March 27th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their prior estimate of $0.09. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2025 earnings at $0.16 EPS and FY2029 earnings at $5.83 EPS.

Separately, Alliance Global Partners restated a “buy” rating on shares of Journey Medical in a research report on Thursday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $9.67.

Journey Medical Stock Up 3.2 %

Shares of DERM opened at $6.11 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The company has a 50-day moving average price of $5.09 and a two-hundred day moving average price of $5.17. The stock has a market cap of $127.64 million, a price-to-earnings ratio of -6.50 and a beta of 0.97. Journey Medical has a 12 month low of $3.20 and a 12 month high of $6.89.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.30. The company had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Insiders Place Their Bets

In other news, CEO Claude Maraoui sold 14,905 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.01, for a total value of $74,674.05. Following the transaction, the chief executive officer now directly owns 2,052,418 shares of the company’s stock, valued at $10,282,614.18. The trade was a 0.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 105,831 shares of company stock valued at $536,622. 13.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of DERM. Kovitz Investment Group Partners LLC bought a new stake in shares of Journey Medical during the third quarter worth $66,000. Geode Capital Management LLC lifted its position in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock worth $613,000 after buying an additional 12,882 shares in the last quarter. PVG Asset Management Corp grew its holdings in Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock worth $947,000 after acquiring an additional 9,005 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Journey Medical in the 4th quarter valued at about $80,000. Finally, Citadel Advisors LLC bought a new position in shares of Journey Medical in the fourth quarter worth about $174,000. 7.25% of the stock is owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.